Dipharma Expands R&D Facility for Small Molecules

Dipharma Francis S.r.l. (Dipharma), a global CDMO and APIs manufacturer, has announced the expansion of their research and development centre for small molecules at their headquarters in Baranzate, Italy.

This new space will increase the available space dedicated to analytical R&D activities by over 130%, strengthening the company’s analytical capabilities and techniques needed for their development of new organic synthesis methods and technologies. The company is set on expanding their reach, targeting a wider range of new APIs and advanced intermediates.

It is designed and equipped according to the latest quality and safety standards, with state-of-the-art instrumentation, including a brand new 500 MHz NMR, and is managed through cloud-based integrated data systems.

Dipharma has long recognized the importance of investing in innovation. This commitment has contributed to over 250 patent and patent applications filed, more than 1200 scientific papers written with Dipharma scientist’s contributions, and numerous products in their pipeline.

Who We Are:

Research and development is the engine of economic growth in an increasingly knowledge-based global economy, however more investment is needed to help boost human creativity, innovation and economic output. 

Swanson Reed is one of Italy’s largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

To find out more about R&D or to determine the eligibility of your business for receiving an R&D tax credit, contact a Swanson Reed R&D Tax Advisor today.

Recent Posts

Leave a Comment